コンテンツへスキップ
Merck
  • Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats.

Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats.

Toxicology (2014-05-28)
Masayuki Kanki, Akira Moriguchi, Daisuke Sasaki, Hikaru Mitori, Atsushi Yamada, Akira Unami, Yoichi Miyamae
要旨

Despite increased focus in recent years on urinary microRNA (miRNA) biomarkers in patients with diabetes and chronic kidney diseases, few studies have explored urinary miRNA markers in drug-induced nephrotoxicity. Here, we attempted to identify urinary miRNA markers suitable for use in detecting cisplatin-induced nephrotoxicity in rats. Cisplatin (6mg/kg) was given as a single intraperitoneal injection to male Sprague-Dawley (SD) rats, and urine collected from Days 4 to 5 for 17h under fed or fasted conditions. MiRNAs were identified using TaqMan(®) Rodent microRNA PCR cards, and rats were euthanized 5 days after administration. Levels of 25 miRNAs were significantly increased in the urine of cisplatin-treated rats under both fed and fasted conditions, while the levels of these miRNAs were decreased in either or both the cortex or outer medulla of the kidney. Analysis of time and dose dependency in the urine from rats treated with cisplatin (1, 3, and 6mg/kg) on Days 1, 3, and 7, showed levels of 25 miRNAs were increased in urine and their appearance correlated with the severity of necrosis in the proximal tubules. Four miRNAs (let-7g-5p, miR-93-5p, miR-191a-5p and miR-192-5p) in urine were measured by absolute quantification, and a strong correlation was found between relative and absolute quantification methods. In summary, we identified 25 miRNAs in urine that were able to be used as non-invasive biomarkers for the detection of cisplatin-induced proximal tubular injury in rats. This study is the first step in demonstrating the potential utility of urinary miRNAs in assessing nephrotoxicity. Further study, such as collaborative programs currently underway in the HESI consortium, will clarify the usability of identified miRNA markers in measurement of other nephrotoxicants and injury-site specificity.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
酸化ジルコニウム(IV), powder, 5 μm, 99% trace metals basis
Sigma-Aldrich
cis-ジアンミン白金(II) ジクロリド, crystalline
Sigma-Aldrich
酸化ジルコニウム(IV), nanopowder, <100 nm particle size (TEM)
Sigma-Aldrich
cis-ジアンミン白金(II)ジクロリド, ≥99.9% trace metals basis
Sigma-Aldrich
クレアチニン, anhydrous, ≥98%
Sigma-Aldrich
酸化ジルコニウム(IV), 99.99% trace metals basis (purity excludes ~2% HfO2)
Sigma-Aldrich
酸化ジルコニウム(IV)分散液, nanoparticles, dispersion, <100 nm particle size (BET), 10 wt. % in H2O
Sigma-Aldrich
酸化ジルコニウム(IV)分散液, nanoparticles, dispersion, <100 nm particle size (BET), 5 wt. % in H2O
シスプラチン, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
trans-白金(II)ジアンミンジクロリド
USP
trans-白金(II)ジアンミンジクロリド, United States Pharmacopeia (USP) Reference Standard
trans-白金(II)ジアンミンジクロリド, European Pharmacopoeia (EP) Reference Standard